Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocotrienol plus bevacizumab in advanced ovarian cancer
2013-004858-18Phase 2Completed
- Sponsor
- Vejle Hospital
- Start
- Dec 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Vejle Hospital. Primary endpoint: Fraction of patients without progression after six months of treatment. Started Dec 2014; status: completed.
02
Drugs
bevacizumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2013-004858-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004858-18.